David C. Brodner, M.D. performed a two-year study to evaluate the safety profile of the only ultra-pure continuous-release melatonin available on the market — REMfresh. The data has been published in a supplement to the journal SLEEP and will be presented in August at Virtual SLEEP 2020. The REMfresh Safety Update at 24 Months (REMSU24) study captured and analyzed serious and non-serious adverse event reports for REMfresh over a 24-month period from March 9, 2017 to March 9, 2019. Dr. Brodner found only 51 non-serious side-effects out of the 320,000 people who used REMfresh to manage their insomnia.